Thrombosis and Coagulation Abnormalities Associated with Cancer
|
|
- Felicity Melton
- 6 years ago
- Views:
Transcription
1 ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 24, No. 1 Copyright 1994, Institute for Clinical Science, Inc. Thrombosis and Coagulation Abnormalities Associated with Cancer ARMAND B. GLASSMAN, M.D. and EVELYN JONES, M.ED., M.T.,(ASCP), C.L.S.(NCA) Vanderbilt University Medical Center, Nashville, TN ABSTRACT Abnormalities of hemostasis and malignancy have been recognized since the 19th century. Thrombosis and hypercoagulability are reported in as many as 60 percent of patients with malignancies. Decreased levels of protein coagulation factors, circulating anticoagulants and platelet numbers, and function changes are reported. The purpose of this work is to report a case of portal thrombosis in a patient with a myeloproliferative disorder and to review protein coagulation and platelet abnormalities associated with malignancies. The clinical laboratory assessment of these abnormalities is reviewed. The patient was a 59-year-old woman who was referred to the Vanderbilt University Medical Center with a diagnosis of septic portal vein thrombosis. After evaluation, it turned out that she had a myeloproliferative disorder and portal vein thrombosis secondary to that. Hypercoagulative states have been reported with a variety of carcinomas and other neoplasms. They may or may not be associated with acquired or genetic deficiencies of antithrombin III, protein C and/or S. Factors I, V, VIII:C, IX, and XI have all been reported as being elevated and implicated in hypercoagulability in patients with neoplasms. Increased platelet turnover and decreased survival have been noted in patients with disseminated tumors. Thromboses with lysis of the thrombus may be monitored by increased levels of fibrin degradation products, D-dimer, fibrinopeptides A and B, and platelet factor IV among others. There are frequently decreases in coagulation inhibitors including antithrombin III, protein C and protein S. These changes lead to a state of low-grade disseminated intravascular coagulopathy where thrombus formation is a more frequent occurrence than is hemorrhage. Treatment for the malignancy, for instance radiation and/or chemotherapy, can have an adverse effect on the hemostasis activity. Among the malignancies associated with abnormalities of hemostasis are mucinous adenocarcinomas and some myeloproliferative disorders. In summary, abnormalities of hemostasis can be a presenting aspect of a variety of malignancies. The diagnosis and therapy of the underlying malignant disorder often has to consider an associated hemostatic abnormality. * Address reprint requests to Armand B. Glassman, M.D., Vanderbilt University Medical Center, st Avenue South, TVC 4605, Nashville, TN /94/ $00.90 Institute for Clinical Science, Inc.
2 2 GLASSMAN AND JONES Introduction Trousseau in 1865 is given credit as the first to describe clearly abnormalities of hemostasis in patients with cancer. Alterations of coagulation and malignancy were described by others in the 1930s and subsequently. These aberrations are varied and complex. Many malignant diseases have been associated with either hyper- or hypocoagulability. The malignancies include carcinomas of the liver, lung, breast, kidney, sarcomas, melanomas, lymphocytic and myeloproliferative disorders. Thrombotic episodes occur in up to 60 percent of patients with mucin secreting adenocarcinomas, myeloproliferative disorders, acute promyelocytic leukemia, and brain tumors.2,8 The objectives of this paper are to: (1) present a brief patient history of a woman with a myeloproliferative disorder and thromboses; (2) review protein coagulation and platelet abnormalities associated with malignancies; and (3) emphasize the laboratory diagnosis and follow-up particularly of patients with malignant disorders and thromboses. Case Report This is a 59-year-old w hite woman who was referred to Vanderbilt University Medical Center (VUMC) with a diagnosis of septic portal vein thrombosis. Over the past five to six weeks, she had experienced episodes of sharp chest pains not associated with activity, but they occasionally radiated down the left arm. Ten days prior to admission, she had dull crushing substernal chest pain that was not relieved by nitroglycerine. Evaluation by electrocardiogram, chest x-ray, and history and physical exam, were essentially normal at that time. Right upper quadrant abdominal tenderness remained. Subsequent radiologic and ultrasound studies identified a partial portal vein occlusion presumably owing to thrombosis. She was admitted for anticoagulation therapy consisting of heparin and subsequently coumarin. Elevation of the alanine transaminase 75 IU/L (reference range 4 to 40 IU/L), aspartate transaminase at 107 IU/L (reference range 4 to 40 IU/L) and alkaline phosphatase at 132 IU/L (reference range 40 to 110 IU/L) were noted. After anticoagulation, the patient was sent home only to return to the hospital two days later. She was now febrile with a temperature of F. Antibiotics were begun. Her prothrombin time was prolonged. There was a slight elevation of her white cells. Packed cell volume was 0.41 and platelets were 141,000 mm3. Radiologic studies identified a complete portal vein thrombosis. There was evidence of hepatosplenomegaly. No evidence of other abdominal varices or gastrointestinal problems were noted. Past m edical history was n on con trib uto ry. The patient had been on prem arin for approximately three months for an elevated cholesterol and osteoporosis. Pertinent laboratory findings: Fibrinogen was 620 mg/dl (reference range 190 to 400 mg/dl). Fibrin split products were 1:256 (reference range less than 1:4). Prothrombin time (PT) and partial thromboplastin time (PTT) values-levels of antithrombin III, protein S, and protein C were all determ ined to be within the reference ranges. A bone marrow biopsy was obtained which revealed a moderately hypercellular marrow with the presence of megakaryocytosis, atypical megakaryocytes and was considered to be suggestive of a myeloproliferative disorder. S u b seq u e n t bone m arrow evaluations revealed a myeloproliferative disorder not otherwise classified. Discussion H y p e r c o a g u l a b i l i t y i n M a l ig n a n c ie s H ypercoagulable states have been reported with a variety of carcinomas and other neoplasms. Often these are associated with acquired or genetic deficiencies in antithrombin III, protein C, and protein S. These abnorm alities have been associated with portal vein thrombosis.3,9 A variety of conditions have been reported to lead to portal vein thrombosis (table I). The patient presen ted h ere had norm al values for antithrombin III, protein S, and protein C. The use of the estrogen compound in her therapy is a known risk factor for v en o us th ro m b o sis and has b e e n reported to be associated with a 2.3 fold increase in risk for patients receiving it. Estrogen use has been reported to be associated with hepatitic vein thrombosis (HVT) in patients with myeloproliferative disorders that are either overt or latent. The HVT has been reported in 10 of 18 cases in one study.1 This prompts suggestion that patients who have sus-
3 THROMBOSIS AND COAGULATION ABNORMALITIES ASSOCIATED WITH CANCER 3 TABLE I Conditions Associated with Portal Vein Thrombosis Specific Cirrhosis Neoplasm - Pancreatic carcinoma - Hepatocellular carcinoma Infection Inflammatory - Pancreatitis Myeloproliferative disorders Idiopathic Non-specific Hypercoagulable states Congenital - AT III deficiency - Protein C deficiency - Protein S deficience Acquired - Pregnancy - Oral estrogen intake - Circulating lupus anticoagulant Diseases - Inflammatory bowel diseases - Systemic lupus erythematous - Behcet's disease - Scleroderma - Idiopathic pulmonary hypertension - Paroxysmal nocturnal hemoglobinuria Other Conditions - Noncirrhotic portal fibrosis Idiopathic fibrosis/hypertension Hepatoportal sclerosis - Blunt trauma - Abdominal surgery - Splenectomy in patients with myeloproliferative disorders - Distal splenorenal shunt surgery - Liver transplantation -Transhepatic obliteration of varices pected neoplasms, particularly myeloproliferative disorders and hepatitic vein thrombosis, not be given estrogen. Neoplastic disorders associated with h y p ercoag u lable states have b een reported w ith increased num bers of platelets or dysfunctional platelets. The platelet count in this patient was slightly below the lower limit of our reference range. It is probable that this lower platelet count was secondary to consumption in th e h e p a titic v ein th ro m b o sis. Although no evidence is shown of activation of plasminogen, tissue activating factors or circulating anticoagulants, this patient did have a positive test for fibrin split products. Fibrin split products are an indication of ongoing thrombosis with attem pts at fib rin o ly sis. In creased fib rin o g e n, fib rin s p lit p ro d u c ts, D-dimer, fibrinopeptide A and B, cryofibrinogens, fibrin monomer, B-beta and related peptides, platelet factor 4, and beta-thromboglobulin may be noted. Altered fibronectin and anti thrombin levels are seen in many individuals with disseminated malignancy. Mucinous adenocarcinomas are frequently associated with thrombus formation. The sialic acid moiety of secreted mucin initiates coagulation by the nonenzymatic activation of Factor X to Factor Xa. In pancreatic carcinoma, systemic trypsin triggers intravascular coagulation events. The neoplasms most frequently associated with disseminated intravascular coagulation (DIC) include myeloproliferative and g astro in testin al cancers (table II). TABLE II Maligancies Associated with Disseminated Intravascular Coagulation Acute promyelocytic leukemia Acute myelomonocytic leukemia Lymphomas (immunoblastic) Hodgkins disease Biliary cancer Breast cancer Colon cancer Gastric cancer Lung cancer Malignant melanoma Ovarian cancer
4 4 GLASSMAN AND JONES Patients with neoplasms can have a range of clinical laboratory findings related to low grade DIC (table III). In a series published in 1991 by Wehmeier et al, of 260 patients with myeloproliferative disorders, 33 were first recognized and a diagnosis of myeloproliferative disorder estab lished because of b leed in g or thrombotic events.10 It was also noted in this group of patients that thrombotic events were less frequent in patients below the age of 40. Overall thrombohemorrhagic events were observed in 48 percent of patients with chronic myeloproliferative disorders.11 This patient s bone marrow was characterized by megakaryocytic abnormal forms. Thrombosis is noted as a major complication in polycythemia vera, essential thrombocythemia and acute promyelocytic leukemia.4 H y p o c o a g u l a b i l i t y Hypocoagulability is usually the result of the thrombotic episodes. Although TABLE III Laboratory Manifestations of Low-grade Disseminated Intravascular Coagulation in Malignancy Microangiopathic hemolytic anemia Shistocytosis Reticulocytosis Leukocytosis Fibrinogen borderline or normal Clotting factors borderline or normal Antithrombin III normal or decreased Protein C and/or S normal or decreased Circulating soluble fibrin monomer Elevated fibrin degradation products Elevated D-dimer Elevated fibrinopeptide A Circulating plasmin Plasminogen normal or decreased Elevated B-beta peptides Platelets normal or borderline low Large young platelets Decreased platelet survival Elevated beta-thromboglobulin there have been reports of circulating anticoagulants and fibrinolytic activities in myeloproliferative disorders, hypocoagulable states are more frequently associated with B lymphocyte malignancies. Multiple myeloma has been reported to be associated with 15 percent to 60 percent of the patients having hemorrhagic com plications. Up to 60 p ercen t of patients with IgM Myeloma or Waldenstrom s macroglobulinemia have been reported as having hemorrhagic complications.5 Acquired von Willebrand s syndrome occurs in situations in which the quantity or the function of the von Willebrand glycoprotein is diminished. Normally, von Willebrand factor (vwf) in plasma complexes and stabilizes factor VIII. The vwf is also important in the interaction betw een endothelium and platelets. An acquired form of von Willebrand disease (vwd) has been reported with multiple myeloma, Waldenstrom s macroglobulinemia, monoclonal gammopathies, hairy cell leukemia, chronic lymphocytic leukemia, and malignant lymphomas.6 Platelet dysfunction and subsequent bleeding is a frequent complication of paraproteinanemias and monoclonal gammopathies. Screening tests that will allow for the detection of the vwd include the bleeding time, the FVIII:C, FVIILvWF, and the FVIILRCoF. The FVIII:C inhibitors can be demonstrated by mixing patient plasma with normal plasma. A normal prothrombin time and thrombin time are expected. Clinically, these may present with mucosal bleeding. Acquired vwd patients are often elderly with no history of bleeding or have no family history for coagulopathies.6 Circulating anticoagulants to factor VIII and abnormalities in the conversion of fibrinogen to fibrin have also been reported. Acquired deficiencies of factor X and IX, as well as V, plasminogen, antithrombin III, proteins C and S, and alpha subunit 2-plasminogen inhibitors
5 THROMBOSIS AND COAGULATION ABNORMALITIES ASSOCIATED WITH CANCER 5 have been reported. The presence of lupus anticoagulants have been reported in Hodgkin s and non-hodgkin s lymphomas. As a clinical entity to be evaluated, it should be noted that one report indicated that 8 of 29 patients with the lupus anticoagulant w ithout clinical evidence of systemic lupus erythematosus had a m alignant diagnosis in the final outcome.7 Screening tests, such as the activated and non-activated partial thromboplastin times, the prothrom bin time and the bleeding times for coagulation are not good p re d ic to rs of th ro m b o sis in patients.7 These observations are consistent with the patient presented here. Conclusion Malignancies, particularly myeloproliferative disorders, are known to be associated with a variety of thrombohemorrhagic phenomena. The cause of this can be abnormalities in platelet numbers and/or function, abnormalities in a variety of protein coagulation factors, the presence of procoagulants being made by the tumor or interrelated factors. The laboratory and the attending physician should be alert to consider an underlying malignancy in a patient who presents with thrombosis and/or a hemorrhagic disorder particularly after the age of 40. References 1. Ba r o s i, G., Bu r a t t i, A., C o s t a, A., L ib e r a t o, L., et al: An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer 68: , BlCK, R. L.: Coagulation abnorm alities in malignancy. Semin. Thromb. Hemost. 18: , C o h e n, J., E d e l m a n, R. R., and C h o p r a, S.: Portal vein thrombosis: a review. Am. J. Med. 92: , F r ie d e n b e r g, W., R o b e r t s, R., a n d D a v id, D.: R e la tio n s h ip o f th ro m b o h e m o rrh a g ic c o m p l ic a t io n s to e n d o t h e l i a l c e l l f u n c t i o n in p a tie n ts w ith c h ro n ic m y e lo p ro life ra tiv e d is o r d e rs. A m. J. H e m a t. 40: , G l a s p y, J. A.: Disturbances in hemostasis in patients w ith B-cell m alignancies. Semin. Thromb. Hemost. 18: , Jakw ay, J. L.: Acquired von Williebrand s disease in malignancy. Semin. Thromb. Hemost. 18: , KUNKEL, L. A.: Acquired circulating anticoagulants in malignancy. Semin. Thromb. Hemost. 18: , SCATES, S. M.: Diagnosis and treatment of cancer re la te d throm bosis. Sem in. T hrom b. Hemost. 18: , T e o f i l i, L., D e S t e f a n o, V., L e o n e, G., MiCALIZZI, P., e t a l: H e m a to lo g ic a l c a u se s o f v e n o u s th ro m b o sis in y o u n g p e o p le : h ig h in c i d e n c e o f m y e lo p ro life ra tiv e d is o rd e r as u n d e r ly in g d i s e a s e in p a t i e n t s w ith s p l a n c h n i c v e n o u s th ro m b o sis. T h ro m b. H a e m o st. 6 7 : , W e h m e i e r, A., D a u m, I., J a m in, H., and Sc h n e id e r, W.: Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. Ann. Hemat. 63: , W e h m e i e r, A., F r ic k e, S., Sc h a r f, R. E., Sc h n e id e r, W., et al: A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders. Eur. J. Haematol. 45: , 1990.
Chapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89
Chapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89 Presented by Jennifer Kurkulonis 1 FOUR MAJOR TYPES OF BLOOD CELLS White blood cells
More informationHaemostasis & Coagulation disorders Objectives:
Haematology Lec. 1 د.ميسم مؤيد علوش Haemostasis & Coagulation disorders Objectives: - Define haemostasis and what are the major components involved in haemostasis? - How to assess the coagulation status?
More informationThe primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:
Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationIndex. Note: Page numbers of article numbers are in boldface type.
Index Note: Page numbers of article numbers are in boldface type. A Abdomen, acute, as cancer emergency, 381 399 in cancer patients, etiologies unique to, 390 392 in perforation, 388 surgery of, portal
More informationACQUIRED COAGULATION ABNORMALITIES
ACQUIRED COAGULATION ABNORMALITIES ACQUIRED COAGULATION ABNORMALITIES - causes 1. Liver disease 2. Vitamin K deficiency 3. Increased consumption of the clotting factors (disseminated intravascular coagulation
More informationEDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION
EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationHEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Hematology MOC exam blueprint Based on feedback from physicians that MOC assessments should
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug
More informationDIC. Bert Vandewiele Fellow Critical Care 23 May 2011
DIC Bert Vandewiele Fellow Critical Care 23 May 2011 Dissiminated Intravascular Coagulopathie 11/3/2011 Dr. Bert Vandewiele 2 Dissiminated Intravascular Coagulopathie = Consumption coagulopathie = Defibrination
More informationHematologic Disorders. Assistant professor of anesthesia
Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's
More informationUNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.
UNIT VI Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav Hemostasis: Prevention of Blood Loss Vascular constriction Formation of a platelet plug Formation of a blood
More informationTopics of today lectures: Hemostasis
Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms of hemostasis - Vascular contraction - Platelets plug - Blood coagulation (clotting) - Structure and functions of platelets - Blood
More informationJuly 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
July 3, 2013 The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Physician Compare Intelligent Search To Whom it May Concern, The American
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More information12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationThis slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion
This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms
More informationThe frequency of disseminated intravascular. Zanco J. Med. Sci., Vol. 18, No. (2),
The frequency of disseminated intravascular coagulopathy in newly diagnosed adult patients with haematological malignancies attending Nanakaly Hospital in Erbil Received: 17/1/2013 Accepted: 23/7/2013
More informationDisseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS
به نام خدا Disseminated Intravascular Coagulation M.Bahmanpour MD Assistant professor IUMS Algorithm for Diagnosis of DIC DIC Score factor score Presence of known underlying disorder No= 0 yes=2 Coagolation
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal radiotherapy, toxic effects of, 636 637 Acute promyelocytic leukemia, associated with acquired bleeding problems, 614 615 Acute renal
More informationBLEEDING DISORDERS Simple complement:
BLEEDING DISORDERS Simple complement: 1. Select the statement that describe the thrombocytopenia definition: A. Marked decrease of the Von Willebrandt factor B. Absence of antihemophilic factor A C. Disorder
More informationDisseminated Intravascular Coagulation (DIC) Seminar. Ron Kopilov 4 th year Medical Student, Tel Aviv University Internal Medicine A 8.3.
Disseminated Intravascular Coagulation (DIC) Seminar Ron Kopilov 4 th year Medical Student, Tel Aviv University Internal Medicine A 8.3.2012 1 Our plan: Understand the pathophysiology Identify risk factors
More informationDiagnosis of hypercoagulability is by. Molecular markers
Agenda limitations of clinical laboratories to evaluate hypercoagulability and the underlying cause for thrombosis what is the INR the lupus anticoagulant and the antiphospholipid antibody syndrome hassouna
More informationThere are two main causes of a low platelet count
Thrombocytopenia Thrombocytopenia is a condition in which a person's blood has an unusually low level of platelets Platelets, also called thrombocytes, are found in a person's blood along with red blood
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Anemia(s), 412 426 categories in morphologic approach to, macrocytic, 412 414 microcytic, 412 414 normocytic, 412 413 categorizing, 412
More informationApproach To A Bleeding Patient
ABDUL MAJEED, RAHUL RAJEEV REVIEW ARTICLE INTRODUCTION Hemostasis is the process of forming clots in the walls of damaged blood vessels and preventing blood loss while maintaining blood in a fluid state
More informationApproach to disseminated intravascular coagulation
Approach to disseminated intravascular coagulation Khaire Ananta Shankarrao 1, Anil Burley 2, Deshmukh 3 1.MD Scholar, [kayachikitsa] 2.Professor,MD kayachikitsa. 3.Professor and HOD,Kayachikitsa. CSMSS
More informationL iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche
L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University
More informationBleeding Disorders: (Hemorrhagic Diatheses) Tests used to evaluate different aspects of hemostasis are the following:
Bleeding Disorders: (Hemorrhagic Diatheses) Excessive bleeding can result from: 1. Increased fragility of vessels. 2. Platelet deficiency or dysfunction. 3. Derangement of coagulation. 4. Combinations
More informationLahey Clinic Internal Medicine Residency Program: Curriculum for Hematology
Lahey Clinic Internal Medicine Residency Program: Curriculum for Hematology Faculty representative: Neil Weiner, MD Resident representative: Guiherme Rabinowits, MD Revision date: February 28, 2006 Goals
More informationINHERITED COAGULOPATHY
Disorder Etiology Pathophysiology and Presentation Lab Findings and Diagnosis Treatment INHERITED COAGULOPATHY HEMOPHILIA A and B Hemophilia A: deficiency in XIII (85%) Hemophilia B: deficiency in IX (15%)
More informationHemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures
Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More informationBleeding disorders. Hemostatic failure: Inappropriate and excessive bleeding either spontaneous or in response to injury.
1 Bleeding disorders Objectives: 1. Discuss briefly the physiology of hemostasis. 2. Define the mechanisms of thrombocytopenia and the relative bleeding risk at any given platelet count. 3. Be able to
More informationMost Common Hemostasis Consults: Thrombocytopenia
Most Common Hemostasis Consults: Thrombocytopenia Cindy Neunert, MS MSCS Assistant Professor, Pediatrics CUMC Columbia University TSHNA Meeting, April 15, 2016 Financial Disclosures No relevant financial
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationGeneral approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013
General approach to the investigation of haemostasis Jan Gert Nel Dept. of Haematology University of Pretoria 2013 Clinical reasons to investigate haemostasis Investigating a clinically suspected bleeding
More informationLAMA SHATAT TTP, ITP, DIC
TTP, ITP, DIC Reduction in platelet number (thrombocytopenia) constitutes an important cause of generalized bleeding. A count less than 100,000 platelets/μl is generally considered to constitute thrombocytopenia.
More informationThe Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011)
The Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011) By Gene Gulati, Ph.D., SH(ASCP) Conflict of Interest None Plan for the Course Review blood smears,
More informationPrimary Exam Physiology lecture 5. Haemostasis
Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation
More informationبسم الله الرحمن الرحيم أوتيتم من العلم إال قليال وما
بسم الله الرحمن الرحيم أوتيتم من العلم إال قليال وما 1 2 Goals of the Lecture: What is the portal vein? How common is PVT? What conditions are associated with PVT? How does patient with PVT present? How
More informationDisseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department
Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department Disseminated intravascular coagulation (DIC, consumptive coagulopathy) is a clinicopathologic
More informationHeme (Bleeding and Coagulopathies) in the ICU
Heme (Bleeding and Coagulopathies) in the ICU General Topics To Discuss Transfusions DIC Thrombocytopenia Liver and renal disease related bleeding Lack of evidence in managing critical illness related
More informationPlatelet Disorders. By : Saja Al-Oran
Platelet Disorders By : Saja Al-Oran Introduction The platelet arise from the fragmentation of the cytoplasm of megakaryocyte in the bone marrow. circulate in the blood as disc-shaped anucleate particles
More informationDISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital
DISSEMINATED INTRAVASCULAR COAGULATION (DIC) Pichika Chantrathammachart MD Division of Hematology, Department of Medicine Ramathibodi Hospital Disseminated intravascular coagulation (DIC) Disseminated
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationCoagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University
In The Name God Coagulation an Overview Dr.Abdolreza Afrasiabi Thalassemia & Heamophilia Genetic Research hcenter Shiraz Medical University Bleeding Clotting Hemostasis Review of platelet function Platelets
More informationYEREVAN STATE MEDICAL UNIVERSITY DEPARTMENT OF HEMATOLOGY COURSE DESCRIPTION HEMATOLOGY
1. Module/unit Code II. 1.2. 2. Module/unit Title Hematology 3. Subject Field Internal Diseases Group 4. Faculty/Department General Medicine, Department of Hematology 5. Programme(s) to which the Doctor
More informationSAUDI FELLOWSHIP TRAINING PROGRAM. Adult Haematology. Final Written Examination 2019
SAUDI FELLOWSHIP TRAINING PROGRAM Adult Haematology Final Written Examination 2019 Examination Format: A. The Saudi fellowship specialty final written examination shall consist of one paper with 80-120
More informationPathology note 8 BLEEDING DISORDER
Pathology note 8 BLEEDING DISORDER Slide75 ( Types of clotting factors deficiency): Today we will talk about public public factor deficiency it could be acquired or inherited, acquired diseases are more
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationThrombosis. By Dr. Sara Mohamed Abuelgasim
Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood
More informationHemostatic System - general information
PLATELET DISORDERS Hemostatic System - general information Normal hemostatic system vessel wall circulating blood platelets blood coagulation and fibrynolysis Bleeding Diathesis inherited or acquired defects
More informationBleeding and Thrombotic Disorders. Kristine Krafts, M.D.
Bleeding and Thrombotic Disorders Kristine Krafts, M.D. Bleeding and Thrombotic Disorders Bleeding disorders von Willebrand disease Hemophilia A and B DIC TTP/HUS ITP Thrombotic disorders Factor V Leiden
More informationHemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins
Hemostasis Learning objectives 14-16 Dr. Mária Dux Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostatic balance! procoagulating activity anticoagulating activity 1 Thrombocytes
More informationChapter 19. Hemostasis
Chapter 19 Hemostasis Hemostasis Hemostasis is the cessation of bleeding stopping potentially fatal leaks important in small blood vessels not effective in hemorrhage excessive bleeding from large blood
More informationBlood Lecture Test Questions Set 2 Summer 2012
Blood Lecture Test Questions Set 2 Summer 2012 1. Leukocytes are attracted to a site of injury or disease by: a. diapedesis b. chemotaxis c. leukocytosis d. heparin e. leukomotosis 2. Leukocytes leave
More informationChapter 46. Care of the Patient with a Blood or Lymphatic Disorder
Chapter 46 Care of the Patient with a Blood or Lymphatic Disorder All items and derived items 2015, 2011, 2006 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved. Components of the Blood Red
More informationBlood Components & Indications for Transfusion. Neda Kalhor
Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets
More information2017/04/21 R1 歐宗頴. Case Discussion
2017/04/21 R1 歐宗頴 Case Discussion Case Demography Name: 18143xxx Age: 14y/o Gender: boy Admission: 2017/04/07 Chief complaint: recurrent fever with RUQ pain for 6 weeks Past History G3P3 full term NSD
More informationThrombosis. Dr. László Terézia
Thrombosis Dr. László Terézia HYPERCOAGULABILITY THROMBOSIS BLOODFLOW ENDOTHEL VIRCHOW ENDOTHEL INJURY L. ventricle: Arteries: surgery infection prosthetic valve hypertension irradiation chemical: cigarette
More informationr). SUPPLEMENTARY/SECOND OPPORTUNITY EXAMINATION PAPER nnmlbih UNIVERSITY Sophia Blaauw INSTRUCTIONS FACULTY OF HEALTH AND APPLIED SCIENCES
r). nnmlbih UNIVERSITY OF SCIEFICE nnd TECHNOLOGY FACULTY OF HEALTH AND APPLIED SCIENCES DEPARTMENT OF HEALTH SCIENCES QUALIFICATION: BACHELOR OF MEDICAL LABORATORY SCIENCES QUALIFICATION CODE: 08BMLS
More informationBleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph
Bleeding Disorders Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph Normal hemostasis The normal hemostatic response involves interactions among: The blood vessel wall (endothelium)
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationHemostasis and. Blood Coagulation
Hemostasis and Blood Coagulation Events in Hemostasis The term hemostasis means prevention of blood loss. Whenever a vessel is severed or ruptured, hemostasis is achieved by several mechanisms: (1) vascular
More informationSaudi Fellowship Training Program. Final Written Examination of Adult Hematology 2018
Saudi Fellowship Training Program Final Written Examination of Adult Hematology 2018 Objectives: Determine the quantity and quality of a hematologist s knowledge base ranked as competent, so that the individual
More informationTHROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO
THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective
More informationCh. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma
Chapt. 45 Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma Inheritance of X-linked gene for Factor VIII hemophilia A Explain the
More informationThrombocytosis and Thrombocythemia: The Laboratory and Clinical Significance of an Elevated Platelet Count
Thrombocytosis and Thrombocythemia: The Laboratory and Clinical Significance of an Elevated Platelet Count WILLIAM M. DAVIS, M.D., AND ALICIA O. MENDEZ ROSS, M.D. Departments of Medicine and Pathology,
More informationChapter 3. Haemostatic abnormalities in patients with liver disease
Chapter 3 Haemostatic abnormalities in patients with liver disease Ton Lisman, Frank W.G. Leebeek 1, and Philip G. de Groot Thrombosis and Haemostasis Laboratory, Department of Haematology, University
More informationIRB protocol Yair Lev, MD 11/25/08
IRB protocol Yair Lev, MD 11/25/08 Abdominal and Pelvic CT as a screening modality for occult malignant disease in unprovoked Venous Thromboembolism: A randomized, controlled prospective study. A. Study
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acute lymphoblastic leukemia, in India, 439 440 pediatric, global approach to, 420 424 core resources in low- and middle-income countries, 423
More informationHematology Review. CCRN exam. The Coagulation Cascade. The Coagulation Cascade. Components include: Intrinsic pathway Extrinsic pathway Common pathway
CCRN exam Hematology Review CCRN Review October 2013 Department of Critical Care Nursing Hematology is 2% of the exam Focus on coagulation cascade, DIC, and HIT Anatomy of the hematologic system Bone marrow
More informationContents SECTION 1: PHYSIOLOGY OF BLOOD
Contents SECTION 1: PHYSIOLOGY OF BLOOD Chapter 1: Overview of Physiology of Blood 1 Normal Haematopoiesis 1 Red Blood Cells 6 White Blood Cells 15 Immune System 27 Megakaryopoiesis 32 Normal Haemostasis
More informationRoutine preoperative coagulation tests: are they necessary?
Routine preoperative coagulation tests: are they necessary? Dr Azzah Alzahrani MD Pediatrics Hematology /Oncology PSMMS Outline Introduction. Brief review of hemostatic mechanisms. A clinical aspect of
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationThrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13
Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13 Mark Cunningham,MD Director, Hematology Laboratory Department of Pathology University of Kansas Medical Center College of American Pathologists
More informationDocument Title: Hemostasis: Platelet and Coagulation Disorders. Author(s): Joseph H. Hartmann (University of Michigan), DO 2012
Project: Ghana Emergency Medicine Collaborative Document Title: Hemostasis: Platelet and Coagulation Disorders Author(s): Joseph H. Hartmann (University of Michigan), DO 2012 License: Unless otherwise
More informationDisorders of Blood Cells & Blood Coagulation
Disorders of Blood Cells & Blood Coagulation HIHIM 409 WBC count RBC count WBC differential Hemoglobin (HGB) Hematocrit (HCT) % of volume occupied by RBCs CBC Red cell indices Mean cell volume (MCV) average
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationTheme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects -
Theme: Making Further Advancements in the Treatment of Hematologic Diseases - Frontline therapies and future prospects - Professor Yutaka YATOMI, M.D., Ph.D., The Department of Clinical Laboratory Medicine,
More informationCOAGULATIONS. Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin)
COAGULATIONS Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin) Haemostasis-blood must be maintained in a fluid state in order to function as a transport system, but must be able to solidify to form a clot following
More informationThe risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance
Original article Annals of Oncology 15: 1490 1494, 2004 doi:10.1093/annonc/mdh385 The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance S. Sallah
More informationBlood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.
Blood clotting It is the conversion, catalyzed by thrombin, of the soluble plasma protein fibrinogen (factor I) into polymeric fibrin, which is deposited as a fibrous network in the primary thrombus. Thrombin
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationرناد زكريا Dr. ahmad Dr. ahmad. P a g e 1
5 رناد زكريا Dr. ahmad Dr. ahmad P a g e 1 Before we start. -This sheet was written according to section 2 s record and reviewed according to section 1 s record by Ruba Hussien with all thanks and I referred
More informationLifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.
LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA 1011.02 Transfusion Criteria Version#2 Department POLICY NO. PAGE NO. Blood Bank Quality Assurance Manual
More informationDr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College
Dr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College AN APPROACH TO BLEEDING DISORDERS NORMAL HEMOSTASIS After injury, 3 processes halt bleeding Vasoconstriction
More informationIntroduction to coagulation and laboratory tests
Introduction to coagulation and laboratory tests Marc Jacquemin Special Haemostasis Laboratory Center for Molecular and Vascular Biology University of Leuven Coagulation in a blood vessel: fibrin stabilises
More informationBleeding Disorders HOPE Maram Al-anbar
Bleeding Disorders HOPE Maram Al-anbar 9-9 - 2014 ^^ Attention Please ^^ We ( correction team of pediatric package^hope/2010^ ) had decided to make one lecture of bleeding disorders in place of the two
More informationMedical Surgical Review Handout- Hematology/Oncology 2016
Medical Surgical Review Handout- Hematology/Oncology 2016 Overview Blood circulates in the cardiovascular system o Carries oxygen to the cells o Carries waste away from the cells Functions of blood o Transportation:
More informationLaboratory Evaluation of Venous Thrombosis Risk
Laboratory Evaluation of Venous Thrombosis Risk Dorothy M. Adcock, MD Volume 17, Number 12 December 2003 Objective: The reader will be able to discuss the concepts of risk factor, risk potential and thrombotic
More informationDISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University
Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)
More information5/5/2010. Goldilocks picture from
Sometimes platelet counts are TOO LOW; Goldilocks and the Three Platelets Robert T. Means, Jr., M.D. Professor & Senior Associate Chair Department of Internal Medicine University of Kentucky Lexington
More informationSCREENING TESTS FOR BLEEDING DISORDERS
THE AMERICAN JOURNAL OP CLINICAL PATHOLOGY Copyright 9 by The Williams & Wilkins Co. Vol., No. 5 Printed in U.S.A. SCREENING TESTS FOR BLEEDING DISORDERS PAUL DIDISHEIM, M.D. Department of Medicine, University
More informationQUESTIONS OF HEMATOLOGY AND THEIR ANSWERS
QUESTIONS OF HEMATOLOGY AND THEIR ANSWERS WHAT IS TRUE AND WHAT IS FALSE? Questions 1 Iron deficiency anemia a) Is usually associated with a raised MCV. b) The MCH is usually low. c) Is most commonly due
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More information